Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Auris Medical Holding (EARS) stocks in Canada

Learn how to easily invest in Auris Medical Holding stocks.

Auris Medical Holding is a biotechnology business based in the US. Auris Medical Holding stocks (EARS.US) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $3.19 – the same closing value as a week prior. Auris Medical Holding employs 8 staff and has a trailing 12-month revenue of around $174,475.

How to buy shares in Auris Medical Holding

  1. Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – EARS – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.

Auris Medical Holding stock price (NASDAQ:EARS)

Use our graph to track the performance of EARS stocks over time.

Auris Medical Holding shares at a glance

Information last updated 2021-11-14.
Latest market close$2.39
52-week range$2.01 - $6.25
50-day moving average $3.25
200-day moving average $3.41
Wall St. target price$14.95
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) $-1.48

Compare online stock trading platforms

Note: The dollar amounts in the table below are in Canadian dollars.

Name Product Finder Rating Stock Trading Fee Account Fee Available Asset Types Offer
FREE TRADES
Wealthsimple Trade
Finder Rating:
★★★★★
3.9 / 5
$0
$0
Stocks, ETFs
Get 2 free stocks when you deposit and trade $150.
Scotia iTRADE
Finder Rating:
★★★★★
3.8 / 5
$4.99 - $9.99
$0
Bonds, Options, Mutual Funds, ETFs, GICs, International Equities
Interactive Brokers
Finder Rating:
★★★★★
4.1 / 5
Min. $1.00, Max. 0.5%
$0
Stocks, Bonds, Options, ETFs, Currencies, Futures
OFFER
CIBC Investor's Edge
Finder Rating:
★★★★★
4 / 5
$4.95 - $6.95
$0 if conditions met, otherwise $100/year
Stocks, Bonds, Options, Mutual Funds, ETFs
Get up to $2,000 cash back. Conditions apply. Offer ends March 1, 2022.
Questrade
Finder Rating:
★★★★★
4.2 / 5
$4.95 - $9.95
$0
Stocks, Bonds, Options, Mutual Funds, ETFs, GICs, International Equities, Precious Metals
Get $50 in free trades when you fund your account with a minimum of $1,000.
Qtrade Direct Investing
Finder Rating:
★★★★★
4.1 / 5
$6.95 - $8.75
$0 if conditions met, otherwise $25/quarter
Stocks, Bonds, Options, Mutual Funds, ETFs, GICs
Get a $50 bonus when you open a new RRSP, TFSA or RESP and start pre-authorized contributions of $200+/month. Valid until March 1, 2022.
loading

Compare up to 4 providers

Online stock trading

Is it a good time to buy Auris Medical Holding stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Auris Medical Holding price performance over time

Historical closes compared with the close of $2.39 from 2021-09-24

1 week (2022-01-10) N/A
1 month (2021-12-17) N/A
3 months (2021-10-17) N/A
6 months (2021-07-21) -26.91%
1 year (2021-01-21) -14.64%
2 years (2020-01-21) 57.24%
3 years (2019-01-18) 484.35%
5 years (2017-01-20) 125.47%

Auris Medical Holding financials

Revenue TTM $174,475
Gross profit TTM $174,475
Return on assets TTM -21.99%
Return on equity TTM -71.91%
Profit margin 0%
Book value $1.47
Market capitalisation $39.2 million

TTM: trailing 12 months

Auris Medical Holding share dividends

We're not expecting Auris Medical Holding to pay a dividend over the next 12 months.

Have Auris Medical Holding's shares ever split?

Auris Medical Holding's shares were split on a 1:20 basis on 30 April 2019. So if you had owned 20 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Auris Medical Holding shares – just the quantity. However, indirectly, the new 1900% higher share price could have impacted the market appetite for Auris Medical Holding shares which in turn could have impacted Auris Medical Holding's share price.

Auris Medical Holding share price volatility

Over the last 12 months, Auris Medical Holding's shares have ranged in value from as little as $2.01 up to $6.25. A popular way to gauge a stock's volatility is its "beta".

EARS.US volatility(beta: 1.4)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Auris Medical Holding's is 1.4048. This would suggest that Auris Medical Holding's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).

Auris Medical Holding overview

Auris Medical Holding Ltd. , a clinical-stage biopharmaceutical company, developing therapeutics that address important unmet medical needs in neurotology, rhinology and allergy, and CNS disorders. The company's Phase 3 programs under the development include Keyzilen (AM-101) for the treatment of acute inner ear tinnitus; and Sonsuvi (AM-111) for the treatment of acute inner ear hearing loss. It is also developing AM-125 that is in Phase 2 clinical trial for the intranasal treatment of acute peripheral vertigo; AM-201, which has completed Phase 1b clinical trial for the prevention of antipsychotic induced weight gain and drowsiness; and AM-301, a drug-free nasal spray for protection against airborne viruses and allergens, as well as AM-102 for the tinnitus treatment. The company has a collaboration and license agreement with INSERM; and Xigen S. A. to develop, manufacture, and commercialize pharmaceutical products, as well as drug delivery devices and formulations for local administration of therapeutic substances to the inner ear for the treatment of ear disorders.

Auris Medical Holding in the news

There are no recent company news

Frequently asked questions

Disclaimer: This information should not be interpreted as an endorsement of futures, stocks, ETFs, CFDs, options or any specific provider, service or offering. It should not be relied upon as investment advice or construed as providing recommendations of any kind. Futures, stocks, ETFs and options trading involves substantial risk of loss and therefore are not appropriate for all investors. Trading CFDs and forex on leverage comes with a higher risk of losing money rapidly. Past performance is not an indication of future results. Consider your own circumstances, and obtain your own advice, before making any trades.

More on investing

More guides on Finder

Go to site